Dermatologic Side Effects of Psychotropic Medications

Psychosomatics

Volumn 55, Issue 1, 2014, Pages 1-20

  Mitkov, Mario V ^a   Trowbridge, Ryan M ^a   Lockshin, Benjamin N ^b,c   Caplan, Jason P ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; HYPNOTIC SEDATIVE AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADVERSE DRUG REACTION; CLINICAL FEATURE; DRUG SAFETY; DRUG WITHDRAWAL; GENERAL HOSPITAL; HUMAN; PSYCHIATRIST; REVIEW; RISK FACTOR; SKIN EXAMINATION; SKIN MANIFESTATION; SYSTEMATIC REVIEW; DRUG ERUPTIONS;

DRUG ERUPTIONS; HUMANS; PSYCHOTROPIC DRUGS;

EID: 84891373073     PISSN: 00333182     EISSN: 15457206     Source Type: Journal    
DOI: 10.1016/j.psym.2013.07.003     Document Type: Review

References (179)

1. Svensson C.K., Cowen E.W., Gaspari A.A. Cutaneous drug reactions. Pharmacol Rev 2001, 53(3):357-379. [Epub 2001/09/08].
2. Lange-Asschenfeldt C., Grohmann R., Lange-Asschenfeldt B., Engel R.R., Ruther E., Cordes J. Cutaneous adverse reactions to psychotropic drugs: data from a multicenter surveillance program. J Clin Psychiatry 2009, 70(9):1258-1265. [Epub 2009/06/23].
3. Drake L.A., Dinehart S.M., Farmer E.R., et al. Guidelines of care for cutaneous adverse drug reactions. American Academy of Dermatology. J Am Acad Dermatol 1996, 35(3 Pt 1):458-461. [Epub 1996/09/01].
4. Schnyder B., Pichler W.J. Mechanisms of drug-induced allergy. Mayo Clin Proc 2009, 84(3):268-272. [Epub 2009/03/03].
5. MacMorran W.S., Krahn L.E. Adverse cutaneous reactions to psychotropic drugs. Psychosomatics 1997, 38(5):413-422. [Epub 1997/10/07].
6. Nayak S., Acharjya B. Adverse cutaneous drug reaction. Indian J Dermatol 2008, 53(1):2-8. [Epub 2008/01/01].
7. Damian D.L., Kim Y.J., Dixon K.M., Halliday G.M., Javeri A., Mason R.S. Topical calcitriol protects from UV-induced genetic damage but suppresses cutaneous immunity in humans. Exp Dermatol 2010, 19(8):e23-e30. [Epub 2009/09/18].
8. Loser K., Beissert S. Regulation of cutaneous immunity by the environment: an important role for UV irradiation and vitamin D. Int Immunopharmacol 2009, 9(5):587-589. [Epub 2009/06/23].
9. Zbytek B., Janjetovic Z., Tuckey R.C., et al. 20-hydroxyvitamin D3, a product of vitamin D3 hydroxylation by cytochrome P450scc, stimulates keratinocyte differentiation. J Invest Dermatol 2008, 128(9):2271-2280. [Epub 2008/03/28].
10. Bigby M., Jick S., Jick H., Arndt K. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. J Am Med Assoc 1986, 256(24):3358-3363. [Epub 1986/12/26].
11. Arndt K.A., Jick H. Rates of cutaneous reactions to drugs. A report from the Boston Collaborative Drug Surveillance Program. J Am Med Assoc 1976, 235(9):918-923. [Epub 1976/03/01].
12. Sarantidis D., Waters B. A review and controlled study of cutaneous conditions associated with lithium carbonate. Br J Psychiatry 1983, 143:42-50. [Epub 1983/07/01].
13. Alvestad S., Lydersen S., Brodtkorb E. Rash from antiepileptic drugs: influence by gender, age, and learning disability. Epilepsia 2007, 48(7):1360-1365. [Epub 2007/05/09].
14. Mehta T.Y., Prajapati L.M., Mittal B., et al. Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian J Dermatol Venereol Leprol 2009, 75(6):579-582. [Epub 2009/11/17].
15. Tassaneeyakul W., Tiamkao S., Jantararoungtong T., et al. Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. Epilepsia 2010, 51(5):926-930. [Epub 2010/03/30].
16. Kaniwa N., Saito Y., Aihara M., et al. HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia 2010, 51(12):2461-2465. [Epub 2011/01/06].
17. Kaniwa N., Saito Y., Aihara M., et al. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2008, 9(11):1617-1622. [Epub 2008/11/21].
18. Ikeda H., Takahashi Y., Yamazaki E., et al. HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions. Epilepsia 2010, 51(2):297-300. [Epub 2009/08/22].
19. McCormack M., Alfirevic A., Bourgeois S., et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011, 364(12):1134-1143. [Epub 2011/03/25].
20. Yip V.L., Marson A.G., Jorgensen A.L., Pirmohamed M., Alfirevic A. HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review. Clin Pharmacol Ther 2012, 92(6):757-765. [Epub 2012/11/08].
21. Kalow W. Ethnic differences in drug metabolism. Clin Pharmacokinet 1982, 7(5):373-400. [Epub 1982/09/01].
22. Ives T.J., Bentz E.J., Gwyther R.E. Dermatologic adverse drug reactions in a family medicine setting. Arch Fam Med 1992, 1(2):241-245. [Epub 1992/11/01].
23. Hajjar E.R., Hanlon J.T., Artz M.B., et al. Adverse drug reaction risk factors in older outpatients. Am J Geriatr Pharmacother 2003, 1(2):82-89. [Epub 2004/11/24].
24. Gayford J.J., Redpath T.H. The side-effects of carbamazepine. Proc R Soc Med 1969, 62(6):615-616. [Epub 1969/06/01].
25. Biederman J., Gonzalez E., Bronstein B., De Monaco H., Wright V. Desipramine and cutaneous reactions in pediatric outpatients. J Clin Psychiatry 1988, 49(5):178-183. [Epub 1988/05/01].
26. Thong B.Y., Tan T.C. Epidemiology and risk factors for drug allergy. Br J Clin Pharmacol 2011, 71(5):684-700. [Epub 2011/04/13].
27. Seishima M., Yamanaka S., Fujisawa T., Tohyama M., Hashimoto K. Reactivation of human herpesvirus (HHV) family members other than HHV-6 in drug-induced hypersensitivity syndrome. Br J Dermatol 2006, 155(2):344-349. [Epub 2006/08/03].
28. Allain H., Chevrant-Breton J., Beneton C., et al. Undesirable dermatologic results of drugs. Result of a drug monitoring survey. Ann Med Interne (Paris) 1983, 134(6):530-536. [Epub 1983/01/01. Consequences dermatologiques indesirables des medicaments. Resultat d'une enquete de pharmacovigilance].
29. Hunziker T., Kunzi U.P., Braunschweig S., Zehnder D., Hoigne R. Comprehensive hospital drug monitoring (CHDM): adverse skin reactions, a 20-year survey. Allergy 1997, 52(4):388-393. [Epub 1997/04/01].
30. Sharma V.K., Sethuraman G., Kumar B. Cutaneous adverse drug reactions: clinical pattern and causative agents-a 6 year series from Chandigarh, India. J Postgrad Med 2001, 47(2):95-99. [Epub 2002/02/08].
31. Hernandez-Salazar A., Rosales S.P., Rangel-Frausto S., Criollo E., Archer-Dubon C., Orozco-Topete R. Epidemiology of adverse cutaneous drug reactions. A prospective study in hospitalized patients. Arch Med Res. 2006, 37(7):899-902. [Epub 2006/09/15], [Epub 2006/09/15].
32. Thong B.Y., Leong K.P., Tang C.Y., Chng H.H. Drug allergy in a general hospital: results of a novel prospective inpatient reporting system. Ann Allergy Asthma Immunol 2003, 90(3):342-347. [Epub 2003/04/03].
33. Fiszenson-Albala F., Auzerie V., Mahe E., et al. A 6-month prospective survey of cutaneous drug reactions in a hospital setting. Br J Dermatol 2003, 149(5):1018-1022. [Epub 2003/11/25].
34. Garnis-Jones S. Dermatologic side effects of psychopharmacologic agents. Dermatol Clin 1996, 14(3):503-508. [Epub 1996/07/01].
35. Warnock J.K., Morris D.W. Adverse cutaneous reactions to antidepressants. Am J Clin Dermatol 2002, 3(5):329-339. [Epub 2002/06/19].
36. Garcia CC, Drug SD. Reactions. American Academy of Dermatology; 2011 [updated August 2011; cited 2013 February 13]; Available from: http://www.aad.org/education-and-quality-care/.
37. Kimyai-Asadi A., Harris J.C., Nousari H.C. Critical overview: adverse cutaneous reactions to psychotropic medications. J Clin Psychiatry 1999, 60(10):714-725. [quiz 26. Epub 1999/11/05].
38. Husain Z., Reddy B.Y., Schwartz R.A. DRESS syndrome: Part I. Clinical perspectives. J Am Acad Dermatol 2013, 68(5). [693 e1-e14. Epub 2013/04/23].
39. Tennis P., Stern R.S. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology 1997, 49(2):542-546. [Epub 1997/08/01].
40. Ganeva M., Gancheva T., Lazarova R., et al. Carbamazepine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: report of four cases and brief review. Int J Dermatol 2008, 47(8):853-860. [Epub 2008/08/23].
41. Bang D., Shah T., Thakker D., Shah Y., Raval A.D. Drug-induced Stevens-Johnson syndrome: case series from tertiary care centre in Gujarat. Pharmacoepidemiol Drug Saf 2012, 21(4):384-395. [Epub 2012/03/01].
42. Yang C.Y., Dao R.L., Lee T.J., et al. Severe cutaneous adverse reactions to antiepileptic drugs in Asians. Neurology 2011, 77(23):2025-2033. [Epub 2011/11/26].
43. Harth Y., Rapoport M. Photosensitivity associated with antipsychotics, antidepressants and anxiolytics. Drug Saf 1996, 14(4):252-259. [Epub 1996/04/01].
44. Sokumbi O., Wetter D.A. Clinical features, diagnosis, and treatment of erythema multiforme: a review for the practicing dermatologist. Int J Dermatol 2012, 51(8):889-902. [Epub 2012/07/14].
45. Assier H., Bastuji-Garin S., Revuz J., Roujeau J.C. Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes. Arch Dermatol 1995, 131(5):539-543. [Epub 1995/05/01].
46. Gupta M.A., Gupta A.K., Haberman H.F. The self-inflicted dermatoses: a critical review. Gen Hosp Psychiatry 1987, 9(1):45-52. [Epub 1987/01/01].
47. Chadwick D., Shaw M.D., Foy P., Rawlins M.D., Turnbull D.M. Serum anticonvulsant concentrations and the risk of drug induced skin eruptions. J Neurol Neurosurg Psychiatry 1984, 47(6):642-644. [Epub 1984/06/01].
48. Chen P., Lin J.J., Lu C.S., et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med 2011, 364(12):1126-1133. [Epub 2011/03/25], [Epub 2011/03/25].
49. Smith H., Newton R. Adverse reactions to carbamazepine managed by desensitisation. Lancet 1985, 1(8431):753. [Epub 1985/03/30].
50. Eames P. Adverse reactions to carbamazepine managed by desensitisation. Lancet 1989, 1(8636):509-510. [Epub 1989/03/04].
51. Beran R.G. Cross-reactive skin eruption with both carbamazepine and oxcarbazepine. Epilepsia 1993, 34(1):163-165. [Epub 1993/01/01].
52. Huang C.W., Tsai J.J., Lai M.L. Lamotrigine-related skin rashes in adults. Kaohsiung J Med Sci 2002, 18(11):566-572. [Epub 2003/01/07].
53. Sadock B.J.K.H., Sadok V.A. Kaplan & Sadock's ynopsis of psychiatry: behavioral sciences/clinical psychiatry 2007, Lippincott Williams & Wilkins, Philadelphia.
54. Wong I.C., Mawer G.E., Sander J.W. Factors influencing the incidence of lamotrigine-related skin rash. Ann Pharmacother 1999, 33(10):1037-1042. [Epub 1999/10/26].
55. Ketter T.A., Wang P.W., Chandler R.A., et al. Dermatology precautions and slower titration yield low incidence of lamotrigine treatment-emergent rash. J Clin Psychiatry 2005, 66(5):642-645. [Epub 2005/05/14].
56. Lorberg B., Youssef N.A., Bhagwagar Z. Lamotrigine-associated rash: to rechallenge or not to rechallenge?. Int J Neuropsychopharmacol 2009, 12(2):257-265. [Epub 2008/10/11].
57. Daily Med: current medication information, Lamictal. National Institutes of Health; 2012 [updated 9/2012; cited 2013 July 29]. Available from: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d7e3572d-56fe-4727-2bb4-013ccca22678%23nlm34070-3.
58. Sullivan J.R., Shear N.H. What are some of the lessons learnt from in vitro studies of severe unpredictable drug reactions?. Br J Dermatol 2000, 142(2):205-207. [Epub 2000/03/24].
59. Tak H.J., Ahn J.H., Kim K.W., et al. Rash in psychiatric and nonpsychiatric adolescent patients receiving lamotrigine in Korea: a retrospective cohort study. Psychiatry Investig 2012, 9(2):174-179. [Epub 2012/06/19].
60. Vestergaard P., Amdisen A., Schou M. Clinically significant side effects of lithium treatment. A survey of 237 patients in long-term treatment. Acta Psychiatr Scand 1980, 62(3):193-200. [Epub 1980/09/01].
61. Gupta A.K., Knowles S.R., Gupta M.A., Jaunkalns R., Shear N.H. Lithium therapy associated with hidradenitis suppurativa: case report and a review of the dermatologic side effects of lithium. J Am Acad Dermatol 1995, 32(2 Pt 2):382-386. [Epub 1995/02/01].
62. Orwin A. Hair loss following lithium therapy. Br J Dermatol 1983, 108(4):503-504. [Epub 1983/04/01].
63. Deandrea D., Walker N., Mehlmauer M., White K. Dermatological reactions to lithium: a critical review of the literature. J Clin Psychopharmacol 1982, 2(3):199-204. [Epub 1982/06/01].
64. White S.W. Lithium and warts. Int J Dermatol 1982, 21(2):107. [Epub 1982/03/01].
65. Ghadirian A.M., Lalinec-Michaud M. Report of a patient with lithium-related alopecia and psoriasis. J Clin Psychiatry 1986, 47(4):212-213. [Epub 1986/04/01].
66. Terui T., Tagami H. Eczematous drug eruption from carbamazepine: coexistence of contact and photocontact sensitivity. Contact Dermatitis 1989, 20(4):260-264. [Epub 1989/04/01].
67. Yasuda S., Mizuno N., Kawabe Y., Sakakibara S. Photosensitive lichenoid reaction accompanied by nonphotosensitive subacute prurigo caused by carbamazepine. Photodermatology 1988, 5(5):206-210. [Epub 1988/10/01].
68. Kohno Y., Ishii A., Shoji S. A case of hair loss induced by carbamazepine. Rinsho Shinkeigaku 2004, 44(6):379-381. [Epub 2004/08/06].
69. Suarez Moro R., Trapiella Martinez L., Avanzas Gonzalez E., Salas Puig J., Fernandez Fernandez C. [Stevens-Johnson syndrome secondary to carbamazepine mediated by photosensitivity]. Ann Med Interna 2000, 17(2):105-106. [Epub 2000/06/01. Sindrome de Stevens-Johnson secundario a carbamazepina mediado por fotosensibilidad].
70. Alvarez-Ruiz S., Delgado Y., Aragues M., Fraga J., Sanchez-Perez J., Fernandez-Herrera J. Mycosis fungoides-type eruptions induced by carbamazepine. Actas Dermosifiliogr 2006, 97(1):43-47. [Epub 2006/03/17. Erupciones de tipo micosis fungoide inducidas por carbamazepina].
71. d'Incan M., Mouillet M.L., Roger H., et al. Cutaneous pseudolymphoma caused by carbamazepine. Ann Dermatol Venereol 1998, 125(1):52-55. [Epub 1998/09/25. Pseudolymphome cutane induit par la carbamazepine].
72. Gerstner T., Lipinski C., Longin E., Konig S. Valproate-induced change in hair color. J Am Acad Dermatol 2008, 58(2 SUPPL):S63-S64. [Epub 2008/01/23].
73. Buka R., Hille R., McCormack P. Yellow nail pigmentation following Depakote therapy. J Drugs Dermatol 2003, 2(5):545-547. [Epub 2003/10/16].
74. Khan T.A., Sheng H., Mercke Y.K., Lippmann S.B. Divalproex-induced alopecia: a case report. Psychiatr Serv 1999, 50(11):1500. [Epub 1999/11/05].
75. Cogrel O., Beylot-Barry M., Vergier B., et al. Sodium valproate-induced cutaneous pseudolymphoma followed by recurrence with carbamazepine. Br J Dermatol 2001, 144(6):1235-1238. [Epub 2001/06/26].
76. Plantin P., Cartier H., Le Bihan G., Clouard P., Lellouche F., Leroy J.P. Drug hypersensitivity syndrome during treatment with valproic acid. Presse Med 1995, 24(34):1624. [Epub 1995/11/11. Syndrome d'hypersensibilite medicamenteuse au cours d'un traitement par acide valproique].
77. Woo Y.S., Bahk W.M., Jon D.I., et al. Rash in adult patients receiving lamotrigine to treat bipolar I disorder in Korea: a multicenter, prospective, naturalistic, open-label trial. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33(7):1147-1152. [Epub 2009/06/23].
78. Huang H.T., Chang C.L., Tzeng D.S. Toxic epidermal necrolysis after sun-exposure probably due to lamotrigine and chlorpromazine. Asian J Psychiatr 2010, 3(4):240-242. [Epub 2010/12/01].
79. Daily med: current medication information. National Institues of Health; 2013 [updated 5/2013; cited 2013 June 29]; Available from: http://dailymed.nlm.nih.gov/dailymed/about.cfm.
80. Prevention CfDCa. Therapeutic drug use. Centers for Disease Control and Prevention. [Updated 8/20/2012; cited 2013 February 11]. Available from: http://www.cdc.gov/nchs/fastats/drugs.htm.
81. Health United States; 2011. With special feature on socioeconomic status and health. National Center for Health Statistics. [cited 2013 February 11]. Available from: http://www.cdc.gov/nchs/data/hus/hus11.pdf%23100.
82. Preskorn S.H. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 1995, 56(6 SUPPL):12-21. [Epub 1995/01/01].
83. Cooper G.L. The safety of fluoxetine-an update. Br J Psychiatry Suppl 1988, (3):77-86. [Epub 1988/09/01].
84. Hedenmalm K., Sundstrom A., Spigset O. Alopecia associated with treatment with selective serotonin reuptake inhibitors (SSRIs). Pharmacoepidemiol Drug Saf 2006, 15(10):719-725. [Epub 2006/06/20].
85. Pai V.B., Kelly M.W. Bruising associated with the use of fluoxetine. Ann Pharmacother 1996, 30(78):786-788. (Epub 1996/07/01).
86. Rohrs S., Geiser F., Conrad R. Citalopram-induced subacute cutaneous lupus erythematosus-first case and review concerning photosensitivity in selective serotonin reuptake inhibitors. Gen Hosp Psychiatry 2012, 34(5):541-545. [Epub 2012/04/27].
87. Nigen S., Knowles S.R., Shear N.H. Drug eruptions: approaching the diagnosis of drug-induced skin diseases. J Drugs Dermatol 2003, 2(3):278-299. [Epub 2003/07/10].
88. Vaccaro M., Borgia F., Barbuzza O., Guarneri B. Photodistributed eruptive telangiectasia: an uncommon adverse drug reaction to venlafaxine. Br J Dermatol 2007, 157(4):822-824. [Epub 2007/07/28].
89. Schwartz T.L. Diaphoresis and pruritus with extended-release venlafaxine. Ann Pharmacother 1999, 33(9):1009. [Epub 1999/09/24].
90. Weiss N.T., Jones L., Chamberlain J.C. A possible case of venlafaxine-induced Stevens-Johnson syndrome. J Clin Psychiatry 2004, 65(10):1431-1433. [Epub 2004/10/20].
91. Dalle S., Becuwe C., Balme B., Thomas L. Venlafaxine-associated psoriasiform palmoplantar keratoderma and subungual hyperkeratosis. Br J Dermatol 2006, 154(5):999-1000. [Epub 2006/04/26].
92. Schmutz J.L., Barbaud A., Trechot P. Escitalopram, labial pigmentation and lichenoid eruption. Ann Dermatol Venereol 2008, 135(4):346. [Epub 2008/04/19. Escitalopram, eruption lichenoide et pigmentation labiale].
93. Zalsman G., Sever J., Munitz H. Hair loss associated with paroxetine treatment: a case report. Clin Neuropharmacol 1999, 22(4):246-247. [Epub 1999/08/12].
94. Rodriguez-Pazos L., Gomez-Bernal S., Montero I., Rodriguez-Granados M., Toribio J. Erythema multiforme photoinduced by paroxetine and herpes simplex virus. Photodermatol Photoimmunol Photomed 2011, 27(4):219-221. [Epub 2011/07/07].
95. Osborne S.F., Stafford L., Orr K.G. Paroxetine-associated psoriasis. Am J Psychiatry 2002, 159(12):2113. [Epub 2002/11/27].
96. Margolese H.C., Chouinard G., Beauclair L., Rubino M. Cutaneous vasculitis induced by paroxetine. Am J Psychiatry 2001, 158(3):497. [Epub 2001/03/07].
97. Mazzatenta C., Peonia G., Martini P. Pruritus induced by interruption of paroxetine therapy. Br J Dermatol 2004, 150(4):787. [Epub 2004/04/22].
98. Pazzagli L., Banfi R., Borselli G., Semmola M.V. Photosensitivity reaction to fluoxetine and alprazolam. Pharm World Sci 1998, 20(3):136. [Epub 1998/06/10].
99. Liao S., Shang J., Tian X., et al. Up-regulation of melanin synthesis by the antidepressant fluoxetine. Exp Dermatol 2012, 21(8):635-637. [Epub 2012/07/11].
100. Seifritz E., Hatzinger M., Muller M.J., Hemmeter U., Holsboer-Trachsler E. Hair loss associated with fluoxetine but not with citalopram. Can J Psychiatry 1995, 40(6):362. [Epub 1995/08/01].
101. Hemlock C., Rosenthal J.S., Winston A. Fluoxetine-induced psoriasis. Ann Pharmacother 1992, 26(2):211-212. [Epub 1992/02/01].
102. Leznoff A., Binkley K.E., Joffee R.T., Levitt A., Richter M.A. Adverse cutaneous reactions associated with fluoxetine strategy for reintroduction of this drug in selected patients. J Clin Psychopharmacol 1992, 12(5):355-357. [Epub 1992/10/01].
103. Breza T.S., Zheng P., Porcu P., Magro C.M. Cutaneous marginal zone B-cell lymphoma in the setting of fluoxetine therapy: a hypothesis regarding pathogenesis based on in vitro suppression of T-cell-proliferative response. J Cutan Pathol 2006, 33(7):522-528. [Epub 2006/07/29].
104. Warnock J.K., Knesevich J.W. Adverse cutaneous reactions to antidepressants. Am J Psychiatry 1988, 145(4):425-430. [Epub 1988/04/01].
105. Parameshwar E. Hair loss associated with fluvoxamine use. Am J Psychiatry 1996, 153(4):581-582. [Epub 1996/04/01].
106. Thedenat B., Loche F., Albes B., Marguery M.C., Bazex J. Acute generalized exanthematous pustulosis with photodistribution pattern induced by sertraline. Dermatology 2001, 203(1):87-88. [Epub 2001/09/11].
107. Schulterbrandt J.G., Raskin A., Reatig N. True and apparent side effects in a controlled trial of chlorpromazine and imipramine in depression. Psychopharmacologia 1974, 38(4):303-317. [Epub 1974/01/01].
108. Narurkar V., Smoller B.R., Hu C.H., Bauer E.A. Desipramine-induced blue-gray photosensitive pigmentation. Arch Dermatol 1993, 129(4):474-476. [Epub 1993/04/01].
109. Warnock J.K., Sieg K., Willsie D., Stevenson E.K., Kestenbaum T. Drug-related alopecia in patients treated with tricyclic antidepressants. J Nerv Ment Dis 1991, 179(7):441-442. [Epub 1991/07/01].
110. Panuska J.R., King T.R., Korenblat P.E., Wedner H.J. Hypersensitivity reaction to desipramine. J Allergy Clin Immunol 1987, 80(1):18-23. [Epub 1987/07/01].
111. Taniguchi S., Hamada T. Photosensitivity and thrombocytopenia due to amitriptyline. Am J Hematol 1996, 53(1):49-50. [Epub 1996/09/01].
112. Milionis H.J., Skopelitou A., Elisaf M.S. Hypersensitivity syndrome caused by amitriptyline administration. Postgrad Med J 2000, 76(896):361-363. [Epub 2000/05/29].
113. Fogarty B.J., Khan K. Drug induced blistering and the plastic surgeon: a case of amitriptyline induced skin necrosis. Burns 1999, 25(8):768-770. [Epub 2000/01/12].
114. Herschthal D., Robinson M.J. Blisters of the skin in coma induced by amitriptyline and clorazepate dipotassium. Report of a case with underlying sweat gland necrosis. Arch Dermatol 1979, 115(4):499. [Epub 1979/04/01].
115. Gisslen H., Mobacken H. Vasculitis in amitriptyline therapy. Dermatol Monatsschr 1969, 155(10):783-785. [Epub 1969/01/01. Vaskulitiden bei Amitriptylin-Behandlung].
116. Walter-Ryan W.G., Kern E.E., Shirriff J.R., Thomas J.M. Persistent photoaggravated cutaneous eruption induced by imipramine. J Am Med Assoc 1985, 254(3):357-358. [Epub 1985/07/19].
117. Angel T.A., Stalkup J.R., Hsu S. Photodistributed blue-gray pigmentation of the skin associated with long-term imipramine use. Int J Dermatol 2002, 41(6):327-329. [Epub 2002/07/09].
118. Perini G., Zara M., Cipriani R., et al. Imipramine in alopecia areata. A double-blind, placebo-controlled study. Psychother Psychosom 1994, 61(3-4):195-198. [Epub 1994/01/01].
119. Saraf K.R., Klein D.F., Gittelman-Klein R., Groff S. Imipramine side effects in children. Psychopharmacologia 1974, 37(3):265-274. [Epub 1974/07/11].
120. Gallelli L., De Fazio S., Corace E., De Sarro G., Garcia C.S., De Fazio P. Generalised urticaria in a young woman treated with clomipramine and after ingestion of codfish. Pharmacopsychiatry 2006, 39(4):154-156. [Epub 2006/07/28].
121. Tunca Z., Tunca M.I., Dilsiz A., Bayol U., Hancioglu M. Clomipramine-induced pseudocyanotic pigmentation. Am J Psychiatry 1989, 146(4):552-553. [Epub 1989/04/01].
122. Johnson N.M., Copeland G.P., Clarke S.W. Severe neutropenia and urticaria with antidepressant therapy. Lancet 1976, 2(7999):1357. [Epub 1976/12/18].
123. Molnar G. Maprotiline-a double-blind study of a new tetracyclic antidepressant in severe depression. Can Psychiatr Assoc J 1977, 22(1):19-23. [Epub 1977/02/01].
124. Lineberry T.W., Peters G.E., Bostwick J.M. Bupropion-induced erythema multiforme. Mayo Clin Proc 2001, 76(6):664-666. [Epub 2001/06/08].
125. McCollom R.A., Elbe D.H., Ritchie A.H. Bupropion-induced serum sickness-like reaction. Ann Pharmacother 2000, 34(4):471-473. [Epub 2000/04/20].
126. Tackett A.E., Smith K.M. Bupropion-induced angioedema. Am J Health Syst Pharm 2008, 65(17):1627-1630. [Epub 2008/08/21].
127. Cohen L.E. Drug eruption secondary to trazodone: a recently introduced antidepressant. J Am Acad Dermatol 1984, 10(2 Pt 1):303-305. [Epub 1984/02/01].
128. Fabre L.F., Feighner J.P. Long-term therapy for depression with trazodone. J Clin Psychiatry 1983, 44(1):17-21. [Epub 1983/01/01].
129. Ford H.E., Jenike M.A. Erythema multiforme associated with trazodone therapy: case report. J Clin Psychiatry 1985, 46(7):294-295. [Epub 1985/07/01].
130. Barth J.H., Baker H. Generalized pustular psoriasis precipitated by trazodone in the treatment of depression. Br J Dermatol 1986, 115(5):629-630. [Epub 1986/11/01].
131. Gautam M. Alopecia due to psychotropic medications. Ann Pharmacother 1999, 33(5):631-637. [Epub 1999/06/16].
132. Warnock J.K. Psychotropic medication and drug-related alopecia. Psychosomatics 1991, 32(2):149-152. [Epub 1991/01/01].
133. Daily med: current medication information, Sertraline. National Institutes of Health; 2008. [Updated 4/2008; cited 2013 June 29]. Available from: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4a0afc61-f83d-4871-86eb-929c9428a1e3%23nlm34084-4.
134. Daily med: current medication information, Celexa. National Institutes of Health 2010 [Updated 12/2010; cited 2013 June 29]. Available from: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6c96373f-6744-49d4-aec5-3720bc993fab#nlm34084-4.
135. Daily med: current medication information, Paroxetine. National Institues of Health 2013 [Updated 5/2013; cited 2013 June 29]. Available from: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d8a896c2-b0c2-4b44-a4e3-cb6a8ea472ee#nlm34084-4.
136. Beasley C.M., Koke S.C., Nilsson M.E., Gonzales J.S. Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis. Clin Ther 2000, 22(11):1319-1330. [Epub 2000/12/16].
137. Brecht S., Courtecuisse C., Debieuvre C., et al. Efficacy and safety of duloxetine 60mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial. J Clin Psychiatry 2007, 68(11):1707-1716. [Epub 2007/12/07].
138. Ban T.A., Guy W., Wilson W.H. Neuroleptic-induced skin pigmentation in chronic hospitalized schizophrenic patients. Can J Psychiatry 1985, 30(6):406-408. [Epub 1985/10/01].
139. Bloom D., Krishnan B., Thavundayil J.X., Lal S. Resolution of chlorpromazine-induced cutaneous pigmentation following substitution with levomepromazine or other neuroleptics. Acta Psychiatr Scand 1993, 87(3):223-224. [Epub 1993/03/01].
140. Zelickson A.S. Skin changes and chlorpromazine. Some hazards of long-term drug therapy. J Am Med Assoc 1966, 198(4):341-344. [Epub 1966/10/24].
141. Ayd F.J. The dermatologic and systemic manifestations of chlorpromazine hypersensitivity; their clinical significance and management. J Nerv Ment Dis 1956, 124(1):84-87. (Epub 1956/07/01).
142. Daily med: current medication information, Chlorpromazine. National Institues of Health; 2013. [Updated 2/2013; cited 2013 June 29]. Available from: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=298de270-99a5-47cc-9116-a91fd6099385#nlm34084-4.
143. Ewing D.G., Einarson T.R. Loxapine as an alternative to phenothiazines in a case of oculocutaneous skin pigmentation. Am J Psychiatry 1981, 138(12):1631-1632. [Epub 1981/12/01].
144. Thami G.P., Kaur S., Kanwar A.J. Delayed reactivation of haloperidol induced photosensitive dermatitis by methotrexate. Postgrad Med J 2002, 78(916):116-117. [Epub 2002/01/25].
145. Bhattacharya A., Roy D., Hazarika S., Das S., Nath K., Saddichha S. Alopecia areata associated with haloperidol decanoate long-acting injection. Aust N Z J Psychiatry 2012, 46(1):69. [Epub 2012/01/17].
146. Buckley C., Thomas V., Lewin J., Harris D., Rustin M.H. Stelazine-induced pigmentation. Clin Exp Dermatol 1994, 19(2):149-151. [Epub 1994/03/01].
147. Suhonen R. Thioridazine photosensitivity. Contact Dermatitis 1976, 2(3):179. [Epub 1976/06/01].
148. Satanove A., McIntosh J.S. Phototoxic reactions induced by high doses of chlorpromazine and thioridazine. J Am Med Assoc 1967, 200(3):209-212. [Epub 1967/04/17].
149. Llambrich A., Lecha M. Photoinduced lichenoid reaction by thioridazine. Photodermatol Photoimmunol Photomed 2004, 20(2):108-109. [Epub 2004/03/20].
150. Emmert B., Schauder S., Palm H., Hallier E., Emmert S. Disabling work-related persistent photosensitivity following photoallergic contact dermatitis from chlorpromazine and olaquindox in a pig breeder. Ann Agric Environ Med 2007, 14(2):329-333. [Epub 2008/02/06].
151. Lovell C.R., Cronin E., Rhodes E.L. Photocontact urticaria from chlorpromazine. Contact Dermatitis 1986, 14(5):290-291. [Epub 1986/05/01].
152. Eliakim M., Ungar H., Moran E. Observations on the effects of chlorpromazine on experimental intrahepatic obstructive jaundice. Harefuah 1960, 58:119-124. [Epub 1960/02/15].
153. Gregoriou S., Karagiorga T., Stratigos A., Volonakis K., Kontochristopoulos G., Rigopoulos D. Photo-onycholysis caused by olanzapine and aripiprazole. J Clin Psychopharmacol 2008, 28(2):219-220. [Epub 2008/03/18].
154. McLean R.M., Harrison-Woolrych M. Alopecia associated with quetiapine. Int Clin Psychopharmacol 2007, 22(2):117-119. [Epub 2007/02/13].
155. Jhirwal O.P., Avasthi A. Ziprasidone-induced skin reaction: a case report from Indian subcontinent. Indian J Psychiatry 2003, 45(1):64-65. [Epub 2003/01/01].
156. Almond D.S., Rhodes L.E., Pirmohamed M. Risperidone-induced photosensitivity. Postgrad Med J 1998, 74(870):252-253. [Epub 1998/07/31].
157. Yun H.W., Lee B.D. Risperidone augmentation with amisulpride: the blue-tongue sign. Psychiatry Clin Neurosci 2012, 66(5):464-465. [Epub 2012/07/28].
158. Bourrain J.L., Paillet C., Woodward C., Beani J.C., Amblard P. Diagnosis of photosensitivity to flupenthixol by photoprick testing. Photodermatol Photoimmunol Photomed 1997, 13(4):159-161. [Epub 1997/08/01].
159. Alroe C., Bowen P. Metoclopramide and prochlorperazine: the blue-tongue sign. Med J Aust 1989, 150(12):724-725. [Epub 1989/06/19].
160. Kubota T., Ishikura T., Jibiki I. Three cases of alopecia areata induced by zotepine. Acta Neurol 1993, 15(3):200-203. [Epub 1993/06/01].
161. Poulsen J. Hair loss, depigmentation of hair, ichthyosis, and blepharoconjunctivitis produced by dixyrazine. Acta Derm Venereol 1981, 61(1):85-88. [Epub 1981/01/01].
162. Loesche C., Dejobert Y., Thomas P. Immediate wheal after topical administration of chlorproethazine. Contact Dermatitis 1992, 26(4):278. [Epub 1992/04/01].
163. Edwards J.G. Adverse effects of antianxiety drugs. Drugs 1981, 22(6):495-514. [Epub 1981/12/01].
164. Magro C.M., Crowson A.N. Drug-induced immune dysregulation as a cause of atypical cutaneous lymphoid infiltrates: a hypothesis. Hum Pathol 1996, 27(2):125-132. [Epub 1996/02/01].
165. Shader R.I. Are any antianxiety agents safer for patients who spend a great deal of time in direct sunlight?. J Clin Psychopharmacol 1992, 12(2):146. [Epub 1992/04/01].
166. Torras H., Manuel Mascaro J., Mascaro J.M. Photo-onycholysis caused by clorazepate dipotassium. J Am Acad Dermatol 1989, 21(6):1304-1305. [Epub 1989/12/01].
167. Loncar C., Franic T., Bilusic M. Toxic epidermal necrolysis caused by flurazepam?. Psychiatr Danub 2005, 17(3-4):236-239. [Epub 2006/01/06].
168. Redondo P., Vicente J., Espana A., Subira M.L., De Felipe I., Quintanilla E. Photo-induced toxic epidermal necrolysis caused by clobazam. Br J Dermatol 1996, 135(6):999-1002. [Epub 1996/12/01].
169. Thomas E., Bellon T., Barranco P., et al. Acute generalized exanthematous pustulosis due to tetrazepam. J Investig Allergol Clin Immunol 2008, 18(2):119-122. [Epub 2008/05/02].
170. Sanchez-Morillas L., Laguna-Martinez J.J., Reano-Martos M., Rojo-Andres E., Ubeda P.G. Systemic dermatitis due to tetrazepam. J Investig Allergol Clin Immunol 2008, 18(5):404-406. [Epub 2008/11/01].
171. Beauquier B., Fahs H. Secondary dermatologic effects of serotonin reuptake inhibitor antidepressants: hypothesis of cross-reacting allergy. Apropos of 2 cases. Encephale 1998, 24(1):62-64. [Epub 1998/04/29. Effets secondaires dermatologiques des antidepresseurs inhibiteurs de la recapture de la serotonine: hypothese d'une allergie croisee. A propos de deux cas].
172. Krasowska D., Szymanek M., Schwartz R.A., Myslinski W. Cutaneous effects of the most commonly used antidepressant medication, the selective serotonin reuptake inhibitors. J Am Acad Dermatol 2007, 56(5):848-853. [Epub 2006/12/07].
173. Herron G., Bourdo S. Jaundice secondary to promazine, and an analysis of possible cross sensitivities between phenothiazine derivatives. Gastroenterology 1960, 38:87-90. [Epub 1960/01/01].
174. Sicari M.C., Lebwohl M., Baral J., Wexler P., Gordon R.E., Phelps R.G. Photoinduced dermal pigmentation in patients taking tricyclic antidepressants: histology, electron microscopy, and energy dispersive spectroscopy. J Am Acad Dermatol 1999, 40(2 Pt 2):290-293. [Epub 1999/02/20].
175. Sierra N.M., Garcia B., Marco J., Plaza S., Hidalgo F., Bermejo T. Cross hypersensitivity syndrome between phenytoin and carbamazepine. Pharm World Sci 2005, 27(3):170-174. [Epub 2005/08/13].
176. Cheshire W.P., Fealey R.D. Drug-induced hyperhidrosis and hypohidrosis: incidence, prevention and management. Drug Saf 2008, 31(2):109-126. [Epub 2008/01/26].
177. Information on carbamazepine (marketed as Carbatrol, Equetro, Tegretol, and generics) with FDA alerts. U.S. Food and Drug Administration; 2007 [updated 1/25/2010; cited 2013 February 13]. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm107834.htm.
178. Phillips E.J., Mallal S.A. Pharmacogenetics of drug hypersensitivity. Pharmacogenomics 2010, 11(7):973-987. [Epub 2010/07/07].
179. Litvak R., Kaelbling R. Dermatological side effects with psychotropics. Dis Nerv Syst 1972, 33(5):309-311. [Epub 1972/05/01].